# CVS HEALTH Corp: overview

CVS · NYSE · CIK 64803 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cvs.md) · [Financials](/companies/cvs/financials.md) · [Filings](/companies/cvs/filings.md) · [Insiders](/companies/cvs/insiders.md)

Latest reported revenue: [$106.10bn](/filings/0000064803-26-000098.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0000064803-26-000098).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [95.4](/filings/0000064803-25-000037.md) | [97.7 d](/filings/0000064803-26-000010.md) | [94.6](/filings/0000064803-26-000052.md) | [98.9](/filings/0000064803-26-000098.md) | [103](/filings/0000064803-25-000037.md) | [106 d](/filings/0000064803-26-000010.md) | [100](/filings/0000064803-26-000052.md) | [106](/filings/0000064803-26-000098.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [0.9%](/filings/0000064803-25-000037.md) | [2.4% d](/filings/0000064803-26-000010.md) | [3.6%](/filings/0000064803-26-000052.md) | [2.4%](/filings/0000064803-26-000098.md) | [(3.1%)](/filings/0000064803-25-000037.md) | [2.0% d](/filings/0000064803-26-000010.md) | [4.7%](/filings/0000064803-26-000052.md) | [4.4%](/filings/0000064803-26-000098.md) |
| Net margin | % | [0.1%](/filings/0000064803-25-000037.md) | [1.7% d](/filings/0000064803-26-000010.md) | [1.9%](/filings/0000064803-26-000052.md) | [1.0%](/filings/0000064803-26-000098.md) | [(3.9%)](/filings/0000064803-25-000037.md) | [2.8% d](/filings/0000064803-26-000010.md) | [2.9%](/filings/0000064803-26-000052.md) | [2.8%](/filings/0000064803-26-000098.md) |
| Diluted EPS | $ per share | [0.07](/filings/0000064803-25-000037.md) | not reported | [1.41](/filings/0000064803-26-000052.md) | [0.80](/filings/0000064803-26-000098.md) | [(3.13)](/filings/0000064803-25-000037.md) | not reported | [2.30](/filings/0000064803-26-000052.md) | [2.31](/filings/0000064803-26-000098.md) |
| Free cash flow | $bn | [(1.4) d](/filings/0000064803-25-000037.md) | [1.1 d](/filings/0000064803-26-000010.md) | [3.8](/filings/0000064803-26-000052.md) | [1.3 d](/filings/0000064803-26-000098.md) | [0.1 d](/filings/0000064803-25-000037.md) | [2.6 d](/filings/0000064803-26-000010.md) | [3.4](/filings/0000064803-26-000052.md) | [5.7 d](/filings/0000064803-26-000098.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [292](/filings/0000064803-24-000007.md) | [322](/filings/0000064803-25-000007.md) | [358](/filings/0000064803-26-000010.md) | [373](/filings/0000064803-26-000010.md) | [402](/filings/0000064803-26-000010.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.6%](/filings/0000064803-24-000007.md) | [2.5%](/filings/0000064803-25-000007.md) | [3.8%](/filings/0000064803-26-000010.md) | [2.3%](/filings/0000064803-26-000010.md) | [1.2%](/filings/0000064803-26-000010.md) |
| Net margin | % | [2.7%](/filings/0000064803-24-000007.md) | [1.3%](/filings/0000064803-25-000007.md) | [2.3%](/filings/0000064803-26-000010.md) | [1.2%](/filings/0000064803-26-000010.md) | [0.4%](/filings/0000064803-26-000010.md) |
| Diluted EPS | $ per share | [6.02](/filings/0000064803-24-000007.md) | [3.26](/filings/0000064803-25-000007.md) | [6.47](/filings/0000064803-26-000010.md) | [3.66](/filings/0000064803-26-000010.md) | [1.39](/filings/0000064803-26-000010.md) |
| Free cash flow | $bn | [15.7](/filings/0000064803-24-000007.md) | [13.5](/filings/0000064803-25-000007.md) | [10.4](/filings/0000064803-26-000010.md) | [6.3](/filings/0000064803-26-000010.md) | [7.8](/filings/0000064803-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cvs/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.75bn | 123,223,409 |  | Reduced −2,696,444 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.62bn | 83,315,369 |  | Added +665,293 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $7.75bn | 74,951,955 |  | Reduced −2,296,687 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $6.24bn | 60,283,408 |  | Added +961,227 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $5.17bn | 50,012,765 |  | Reduced −1,767,351 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $3.50bn | 33,801,113 |  | Added +11,233,381 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.08bn | 29,899,653 |  | Added +440,611 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $2.99bn | 28,920,617 |  | Reduced −2,276,273 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.76bn | 26,637,259 |  | Added +639,911 |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $2.52bn | 24,329,151 |  | Added +4,316,819 |

## Recent filings

[All 1,951 filings](/companies/cvs/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-17 | 16:19 ET | [8-K](/filings/0001193125-26-354096.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354096 |
| 2026-08-05 | 06:33 ET | [10-Q](/filings/0000064803-26-000098.md) | Quarterly report, period 2026-06-30 | 0000064803-26-000098 |
| 2026-08-05 | 06:32 ET | [8-K](/filings/0000064803-26-000097.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000064803-26-000097 |
| 2026-05-18 | 16:13 ET | [8-K](/filings/0000064803-26-000082.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000064803-26-000082 |
| 2026-05-06 | 06:33 ET | [10-Q](/filings/0000064803-26-000052.md) | Quarterly report, period 2026-03-31 | 0000064803-26-000052 |
| 2026-05-06 | 06:31 ET | [8-K](/filings/0000064803-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000064803-26-000051 |
| 2026-04-03 | 16:05 ET | [DEF 14A](/filings/0001308179-26-000201.md) | Proxy statement, period 2026-05-14 | 0001308179-26-000201 |
| 2026-03-19 | 16:08 ET | [8-K](/filings/0000064803-26-000017.md) | 5.02 Departure or appointment of officers or directors | 0000064803-26-000017 |
| 2026-02-10 | 06:36 ET | [10-K](/filings/0000064803-26-000010.md) | Annual report, period 2025-12-31 | 0000064803-26-000010 |
| 2026-02-10 | 06:31 ET | [8-K](/filings/0000064803-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000064803-26-000009 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000064803-26-000010.md), filed Feb 10, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f0a6e9be-932d-4ee6-bb27-2dd85a53a6e2)

## About the filer

- CIK: 64803
- Tickers: CVS
- Exchange: NYSE
- SIC code: 5912 Retail-Drug Stores and Proprietary Stores
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.